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Abstract
Introduction: AMG 108 is a fully human, immunoglobulin subclass G2 (IgG2) monoclonal antibody that binds the
human interleukin-1 (IL-1) receptor type 1, inhibiting the activity of IL-1a and IL-1b. In preclinical studies, IL-1
inhibition was shown to be beneficial in models of osteoarthritis (OA). The purpose of this two-part study was to
evaluate the safety and pharmacokinetics (PK; Part A) and clinical effect (Part B) of AMG 108 in a double-blind,
placebo-controlled, multiple-dose study in patients with OA of the knee.
Methods: In Part A, patients received placebo or AMG 108 subcutaneously (SC; 75 mg or 300 mg) or intravenously
(IV; 100 mg or 300 mg) once every 4 weeks for 12 weeks; in Part B, patients received placebo or 300 mg AMG 108
SC, once every 4 weeks for 12 weeks. The clinical effect of AMG 108 was measured in Part B by using the Western
Ontario and McMaster Universities (WOMAC) osteoarthritis index pain score.
Results: In Part A, 68 patients were randomized, and 64 received investigational product. In Part B, 160 patients
were randomized, and 159 received investigational product. AMG 108 was well tolerated. Most adverse events
(AEs), infectious AEs, serious AEs and infections, as well as withdrawals from the study due to AEs occurred at
similar rates in both active and placebo groups. One death was reported in an 80-year-old patient (Part A, 300 mg
IV AMG 108; due to complications of lobar pneumonia). AMG 108 serum concentration-time profiles exhibited
nonlinear PK. The AMG 108 group in Part B had statistically insignificant but numerically greater improvement in
pain compared with the placebo group, as shown by the WOMAC pain scores (median change, -63.0 versus -37.0,
respectively).
Conclusions: The safety profile of AMG 108 SC and IV was comparable with placebo in patients with OA of the
knee. Patients who received AMG 108 showed statistically insignificant but numerically greater improvements in
pain; however, minimal, if any, clinical benefit was observed.
Trial Registration: This study is registered with ClinicalTrials.gov with the identifier NCT00110942.
Introduction
Osteoarthritis (OA) is a chronic, painful, and potentially
disabling disease of the joints that is manifested by carti-
lage damage, changes in the underlying bone, and vary-
ing degrees of synovial inflammation. The prevalence of
OA increases with age; 60% to 70% of individuals aged
70 to 80 years have pathologic evidence of OA [1].
The exact cause of OA is unknown. Recent debate sug-
gests that cytokines produced by activated synovial cells
or articular cartilage may be as important in the patho-
genesis of OA as a concomitant response to mechanical
forces or molecular events from the cartilage and syno-
vium [2]. Cytokines such as interleukin-1 (IL-1) stimulate
the synthesis of proteolytic enzymes such as matrix
metallo-proteinases, nitric oxide (NO), prostaglandins,
and other mediators and effectors of tissue destruction
[3]. IL-1 also inhibits chondrocyte repair of degraded car-
tilage extracellular matrix [4]. In animal models, IL-1 has
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glycosaminoglycan (GAG) release, in a NO-dependent
manner [5,6]. A relative deficiency of endogenous IL-1
receptor antagonist (IL-1ra), the natural antagonist to IL-
1b e t a( I L - 1 b), has been found in the synovial fluid [7]
and diseased cartilage tissue of patients with OA [8]. Car-
tilage from OA patients who had undergone joint-repla-
cement surgery has also been shown to respond to IL-1b
stimulation with higher NO production than RA cartilage
[8]. Animal studies have suggested that intraarticular (IA)
injections of IL-1ra may slow the progression of cartilage
lesions in OA [9-12]. These findings suggest that block-
ing the activity of IL-1b may protect against structural
changes in OA [13,14]. Finally, IL-1 antagonists may also
play a role in the pain of OA [15]. In a small study of
patients with OA, IA injections of the competitive inhibi-
tor of IL-1, anakinra, were well tolerated and contributed
to some improvements in their pain [16].
AMG 108 is a fully human, immunoglobulin subclass
G2 (IgG2) monoclonal antibody that binds the third
immunoglobulin domain of the interleukin-1 receptor
type 1 (IL-1R1) and nonselectively inhibits the activity
of both forms of IL-1 (IL-1a and IL-1b). Inhibiting the
proinflammatory effects of these IL-1 isoforms with
AMG 108 may be useful in treating OA.
The objectives of this two-part study were to compare
the safety and pharmacokinetics (PK) of AMG 108, given
either subcutaneously (SC) or intravenously (IV), in a
multiple-dose, dose-ranging study (Part A), and to deter-
mine the clinical effect (by using the Western Ontario
and McMaster Universities (WOMAC) osteoarthritis
index pain score) of multiple administrations of a
selected dose of AMG 108 versus placebo given SC to
patients with active OA of the knee (Part B).
Materials and methods
Patients
Eligible patients were 30 years old or older and had OA of
the knee that met the 1987 American College of Rheuma-
tology (ACR) [17] classification criteria (knee pain, radio-
graphic osteophytes, and one or more of the following: age
older than 50 years; morning stiffness, 30 minutes or less;
crepitus on motion); and radiographic evidence of tibiofe-
moral-compartment knee OA within 12 weeks of screen-
ing. An index knee was identified at baseline for all study
evaluations of clinical benefit; in addition to this diagnosis
of OA, patients in Part A were required to have the pre-
sence of a knee effusion in the index joint, and patients in
Part B were required to have index knee pain at a level
more than 30 mm on 100-mm visual analog scale (VAS).
Patients who had been taking any over-the-counter
nutritional supplements, or nonprescribed supplements
(for example, glucosamine, chondroitin sulfate, shark car-
tilage, diacerhein, soya extract), or nonsteroidal anti-
inflammatory drugs (NSAIDs) must have been taking a
stable dose for > 2 months; any utilization of physical
therapy, biomechanical devices, or orthotic support also
must have been stable for > 2 months. Patients who were
receiving NSAID therapy must have discontinued therapy
for at least 5 half-lives of the particular NSAID before
randomization into the study.
Patients were excluded if their weight was > 125 kg or if
they had end-stage or bone-on-bone OA (Kellgren-Lawr-
ence 4), symptomatic hip OA ipsilateral to the index knee,
isolated OA of the femoropatellar joint, inflammatory
arthropathy, or diagnosis of a condition other than knee
OA that the investigator thought could cause or affect
pain in the index knee. Patients also were excluded if they
had received any previous AMG 108, anakinra, or other
experimental IL-1 inhibitor; or, at the time of study entry,
had received an investigational monoclonal antibody
within 6 months; had received viscosupplementation ther-
apy within 3 months; had participated in a trial of an
investigational drug or device within 2 months, had
received an IA or systemic corticosteroid injection within
1 month; or were using neuromodulatory agents as
analgesic therapy for OA. They could not have had a
malignancy within 5 years (with the exception of basal cell
or in situ cancer); history of recurrent chronic infections,
active tuberculosis, or antibodies to human immunodefi-
ciency virus or hepatitis C; known or suspected suscept-
ibility to infectious disease; significant hematologic disease;
elevated serum creatinine or liver-function tests (≥1.5
times upper limit of normal); uncontrolled or clinically sig-
nificant systemic disease (for example, diabetes mellitus,
cardiovascular disease, or hypertension); or any other con-
dition that, in the opinion of the investigator, would inter-
fere with the interpretation of the study results. Women
were excluded if they were pregnant or nursing or were
not using adequate contraception (if of childbearing
potential).
Particular attention was given to patient neutrophil
counts, with enrollment into the study to be stopped by
the data-monitoring committee if an increased rate of
neutropenia was observed. Specifically, for each patient,
neutrophil counts were analyzed 1 to 2 days before dos-
ing (days 28 and 56); and dosing was stopped if the pre-
dose neutrophil count was < 1.00 × 10
9/L.
Study design
This was a two-part, randomized, double-blind, placebo-
controlled, multiple-dose study in patients with OA. In
Part A, the dose-ranging portion of the study, 64 patients
were randomized 3:1 in each of four cohorts (12 active;
four placebo) to receive AMG 108 SC (75 mg or 300 mg)
or IV (100 mg or 300 mg) or placebo every 4 weeks for
12 weeks (for a total of three doses of investigational pro-
duct). In Part B, 160 patients were randomized 1:1 to
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same dosing schedule.
For the 10- and 300-mg IV dose groups, AMG 108
(30 mg/ml) or placebo in sterile 5% dextrose in water
(D5W) was administered as a 100-ml IV infusion over a
30-minute period by using a peristaltic pump. For the
75-mg and 150-mg SC dose groups, AMG 108 (100 mg/
ml) or placebo was administered as a single, SC injec-
tion (0.75 ml or 1.5 ml, respectively) in the subject’s
anterior abdominal wall. For the 300-mg SC dose group,
AMG 108 (100 mg/ml) or placebo was administered as
two 1.5-ml SC injections at approximately the same
time of day and at least 2 cm apart on the anterior
abdominal wall.
Efficacy analyses in Part B included two substudies: a
main substudy using the WOMAC osteoarthritis index
pain score conducted at all study sites (145 patients), and
a minor substudy of the delayed gadolinium-enhanced
magnetic resonance imaging of cartilage (dGEMRIC)
conducted at only one study site (because only 15 of the
desired 30 patients were enrolled, the sample was too
small to draw meaningful conclusions; however, for com-
pleteness, dGEMRIC methods and results are included in
Additional File 1). After administration of the last dose in
both Part A and Part B, all patients were followed up for
8 weeks ( < 300-mg dose cohorts) or 12 weeks (300-mg
dose cohorts).
The study was conducted according to the Declaration
of Helsinki and the International Conference on Harmo-
nisation Tripartite Guideline on Good Clinical Practice.
Approvals from appropriate research ethics committees
were obtained from each participating study center. All
patients provided written informed consent before parti-
cipating. An external Data Monitoring Committee moni-
tored patient safety throughout the study.
End points
The primary end point in Part A of the study was the
safety of AMG 108; additional end points included the
PK) of AMG 108. In Part B, the primary end point was
the clinical efficacy of AMG 108 (change from baseline
to week 6 in the WOMAC pain score); additional end
points included the safety and PK of AMG 108.
Safety end points in both parts of the study included
treatment-emergent adverse events (AEs), infectious
AEs, serious AEs and infections, injection-site reactions,
and laboratory abnormalities.
In Part A of the study, serum samples were collected
from all patients for analysis of AMG 108 concentrations
at the following predefined time points: predose on day
1; and postdose day 1 at 30 minutes and 8 hours, and on
days 2, 3, 7, 14, 21, 28, and 41; predose on day 56; and
postdose day 56 at 30 minutes and 8 hours, and on days
57, 58, 63, 70, 77, 84, 98, and 112. Patients receiving >
100-mg doses also had serum collected on days 126 and
140. A subset of patients in the first two cohorts had
additional samples collected at prespecified time points
more frequently during the 2 days after the first dose
(day 1) and the third dose (day 56). Synovial fluid sam-
ples were collected at screening for all patients and at
one of the following time points (n = 4 per time point):
day 2, 7, 14, or 28. In Part B of the study, serum samples
were collected for PK analysis at day 1 (predose), and at
weeks 2, 4, 6, 8, 10, 12, 14, 16, and 20. Synovial fluid sam-
ples were not collected in Part B.
In Part B, the primary efficacy end point was the
change from baseline to week 6 in the WOMAC pain
score. Other efficacy end points included change in sub-
component (function and stiffness) and composite
WOMAC scores from baseline to weeks 6 and 12.
Change in physician and patient global assessments of
pain, the SF-36, and the EQ-5D were also assessed in
Part B.
Biochemical analysis
Serum samples were analyzed for AMG 108 concentra-
tions by using a validated enzyme-linked immunosorbent
assay (ELISA) at MDS Pharma Services (Quebec,
Canada). Non-compartmental analyses were performed
by using WinNonlin Professional Software (Version 4.1e,
Pharsight Corporation, Mountain View, CA) to estimate
the maximum observed serum concentration after dosing
(Cmax), the time to reach Cmax (tmax), the observed serum
concentrations of AMG 108, the area under the concen-
tration-time curve during the dosing interval (AUC0-τ),
and the trough concentration after the first and third
doses.
C-reactive protein (CRP) was determined by using a
highly sensitive latex particle-enhanced immunoturbidi-
metric assay that compares the laboratory sample with
standard CRP dilutions. The assay was performed at
ICON Clinical Research (Farmingdale, NY). Elevated
bilirubin, hemoglobin, and lipids did not interfere in the
assay.
Statistical analysis
Patient data were analyzed according to randomized
treatment arm regardless of actual treatment received
during the study. The safety dataset included all patients
who received ≥1 dose of investigational product.
Efficacy end points in Part A were exploratory end
points, and sample size in Part A was too small for infer-
ential statistical analysis on the efficacy end points. In
Part B, the data set used for analysis of the primary effi-
cacy end point included all Part B randomized patients
who participated in the WOMAC study (n = 145). The
primary end point was the change in the WOMAC pain
score from day 1 to week 6 in patients administered
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size of 0.60 (that is, the expected difference in means
between the placebo arm and AMG 108 arm is 60 on a
500-point WOMAC), a sample size of 66 patients per
a r m( 3 0 0m ga n dp l a c e b o )w o u l dh a v e≥90% power to
detect, at the 5% significance level, a difference between
the AMG 108 arm and the placebo arm by using a Wil-
coxon rank-sum test. The total sample size was adjusted
for a possible 10% drop-out rate during the study. For
the primary analyses of efficacy in Part B of the study, the
last-observation-carried-forward (LOCF) method was
used to impute missing data; observed data also were
presented. The data set used for analysis of the secondary
and non-MRI related exploratory efficacy end points
included all randomized patients (n = 160). Stratification
of patients by baseline WOMAC was performed as a post
hoc analysis.
Results
Patient disposition and disease characteristics
Patient disposition is presented in Figure 1. In Part A,
68 patients were randomized, four patients did not
receive investigational product because of ineligibility,
and 64 patients were dosed. Two patients did not com-
plete Part A of the study: one died on day 53 after
receiving two doses of 300 mg AMG 108 IV; the other
discontinued because of personal reasons. In Part B, 80
patients were randomized to 300 mg AMG 108 SC, and
80 patients, to placebo; of the 160 patients, 145 were
randomized to the WOMAC substudy, and 15 were ran-
domized to the dGEMRIC study. Study completion in
Part B was similar between the treatment groups: 159
patients (99%) received one or more doses of investiga-
tional product; 88.8% of patients in the AMG 108
group, and 90.0% in the placebo group completed the
study.
Demographics and baseline disease characteristics
were well balanced among the groups (Table 1). The
majority of patients were women (Part A, 66%; Part B,
68%), and most were white (Part A, 98%; Part B, 83%).
The mean age was 61 years for patients in both parts of
the study. The mean duration of OA at baseline of Part
A was 8 years for the AMG 108 group and 10 years for
the placebo group; for Part B, it was 6 years for both
groups.
No patients in Part A of the study were taking NSAIDs
at baseline; however, the majority (63%) of patients in
Part B were taking NSAIDs before enrollment in the
study. Patients were required to discontinue NSAIDs
within at least 5 half-lives before randomization; NSAIDs
228 patients enrolled 
Part A – 68 patients  Part B – 160 patients 
Not treated (n 
= 4) 
AMG 108 
100 mg IV 
(n = 12) 
1 
discontinued 
(1) Admin. 
decision 
15 
completed 
study 
AMG 108 
300 mg IV 
(n = 12) 
AMG 108 
300 mg SC 
(n = 12) 
AMG 108 
75 mg SC 
(n = 12) 
Placebo 
(n = 16) 
0 discon-
tinued 
1 
discontinued 
(1) Death 
12 
completed 
study 
11 
completed 
study 
12 
completed 
study 
12 
completed 
study 
AMG 108 
300 mg SC 
(n = 80) 
Placebo 
(n = 79) 
7 
discontinued 
(1) Admin. 
decision 
(1) AE 
(3) Withdrew 
consent 
(2) Lost to 
follow-up 
 
9 
discontinued 
(2) Admin. 
decision 
(1) AE 
(4) Withdrew 
consent 
(1) Lost to 
follow-up 
(1) Protocol 
deviation 
 
72 
completed 
study 
71 
completed 
study 
Not treated (n 
= 1) 
0 discon-
tinued 
0 discon-
tinued 
Figure 1 CONSORT diagram. Admin. Decision, administrative decision; AE, adverse event; IV, intravenous; SC, subcutaneous.
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apy during the study.
Safety
AMG 108 was well tolerated during the two-part study.
Most AEs, infectious AEs, serious AEs and infections,
and withdrawals from study due to AEs occurred at
similar rates in the AMG 108 and placebo groups
(Table 2).
One patient in Part A (AMG 108, 300 mg IV), an 80-
year-old man with an ongoing history of hypertension
and asthma at study entry, died during the study. He had
mild neutropenia (absolute neutrophil count (ANC) 1.92
×1 0
9/L) and symptoms of upper respiratory infection
before his second dose of study drug. One week after a
second dose of AMG 108, the patient was hospitalized
with respiratory failure due to lobar pneumonia; at the
time of admission, his ANC was 1.3 × 10
9/L. By the
Table 1 Baseline demographics and disease characteristics
Part A Part B
AMG 108
Placebo
(n = 16)
100 mg IV
(n = 12)
300 mg IV
(n = 12)
300 mg SC
(n = 12)
75 mg SC
(n = 12)
All AMG 108
(n = 48)
Placebo (n
= 80)
AMG 108 300 mg
SC (n = 80)
Mean age (years) 60.8 61.1 62.8 59.6 62.3 61.4 60.1 61.3
Female, n (%) 10 (63) 11 (92) 7 (58) 5 (42) 9 (75) 32 (67) 54 (68) 54 (68)
Ethnicity, n (%)
White 15 (94) 12 (100) 12 (100) 12 (100) 12 (100) 48 (100) 66 (83) 67 (84)
Black 1 (6) 0 0 0 0 0 2 (3) 7 (9)
Hispanic - - - - - - 12 (15) 6 (8)
Mean weight (kg) 83.8 79.9 90.7 85.5 82.4 84.6 87.6 88.2
Mean BMI (kg/m
2) 30.4 30.8 31.9 29.8 30.9 30.8 31.9 32.0
Duration of OA
(years)
9.6 6.9 10.2 6.6 10.0 8.4 6.1 6.1
Kellgren-Lawrence
score (n (%))
1 2 (13) 3 (25) 1 (8) 0 3 (25) 7 (15) 4 (5) 1 (1)
2 4 (25) 3 (25) 7 (58) 5 (42) 4 (33) 19 (40) 30 (38) 40 (50)
3 10 (63) 6 (50) 4 (33) 7 (58) 5 (42) 22 (46) 46 (58) 39 (49)
BMI, body mass index; IV, intravenous; OA, osteoarthritis; SC, subcutaneous.
Table 2 Summary of adverse events
IV Administration SC Administration
Number (%) of patients with Placebo
(n =8 )
100 mg
(n = 12)
300 mg
(n = 12)
All AMG 108
(n = 24)
Placebo
(n = 88)
75 mg
(n = 12)
300 mg
(n = 94)
Any adverse event 8 (100) 12 (100) 12 (100) 24 (100) 74 (84) 12 (100) 77 (82)
Most common AE
Headache 4 (50) 9 (75) 7 (58) 16 (57) 22 (25) 4 (33) 15 (16)
Upper respiratory tract
infection
1 (13) 2 (17) 5 (42) 7 (29) 7 (8) 6 (50) 9 (10)
Infection 3 (38) 4 (33) 8 (67) 12 (50) 18 (21) 7 (58) 25 (27)
Injection-site reaction 1 (13) 1 (8) 2 (17) 3 (13) 3 (3) 0 7 (7)
Treatment-related AE 5 (63) 8 (67) 6 (50) 14 (58) 10 (11) 0 28 (30)
AE leading to study
discontinuation
0 0 0 0 1 (1) 0 1 (1)
Serious AE 0 0 2 (17) 2 (8) 3 (3) 0 2 (2)
Treatment-related SAE 0 0 1 (8) 1 (4) 0 0 1 (1)
Serious infectious AE 0 0 1 (8) 1 (4) 2 (2) 0 1 (1)
Death 0 0 1 (8) 1 (4) 0 0 0
AE, adverse event; IV, intravenous; SAE, serious adverse event; SC, subcutaneous. SAEs were reported by two patients in the 300-mg IV group (hemorrhagic
diarrhea and unstable angina in one; and lobar pneumonia, respiratory failure, multiorgan failure, sepsis, neutropenia, and leukopenia in the other); two patients
in the 300-mg SC group (pancreatitis in one; and pneumonia and supraventricular tachycardia in the other); and three patients in the placebo SC group
(arthropod bite and Staphylococcus infection in one; abdominal pain in the second; and coronary artery disease in the third). All serious infectious AEs have been
listed as SAEs above and include one patient in the 300-mg IV group (lobar pneumonia and sepsis); one patient in the 300-mg SC group (pneumonia); and two
patients in the placebo SC group (Staphylococcus infection in one and abdominal pain in the other).
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9/L; two
days later, his ANC increased to 8.9 × 10
9/L and further
rebounded to 24.3 × 10
9/L. A bacterial agent was not
identified. Despite intensive resuscitative and life-support
treatment, the patient’s condition worsened, and he died,
25 days after the last injection of AMG 108, of lobar
pneumonia, respiratory failure, multiorgan failure, and
sepsis, which the investigator considered related to the
investigational product.
Total numbers of adverse events between 300 mg SC
AMG 108 administration and SC placebo administration
(the two largest groups) were well balanced at 82% (77 of
94) and 84% (74 of 88), respectively. The overall inci-
dence of infections in these two SC groups appeared to
be higher in the AMG 108 group at 27% (25 of 94) versus
21% (18 of 88) for placebo; however, the incidence of ser-
ious infectious AEs was 1% (1 of 94) for AMG 108 and
2% (2 of 88) for placebo. The most frequently reported
infectious AE was upper respiratory infection (URI) in
10% (9 of 94) of the 300-mg SC AMG 108 group and 8%
(7 of 88) of the placebo SC group. One death occurred in
the entire study, as described earlier.
Injection-site reactions also occurred more frequently in
the AMG 108 group than in the placebo group (7% versus
3%, respectively, in Part B; Table 2), but most were mild
or moderate in severity, and no patient withdrew from the
study because of an injection-site reaction.
No clinically significant changes in clinical laboratory
results were observed, with the exception of expected
decreases in ANC in the AMG 108 groups of both Part A
and Part B of the study. In Part B, mean neutrophil
counts at baseline were 4.17 and 4.29 × 10
9/L for AMG
108 and placebo cohorts, respectively. At week 6, the
mean neutrophil counts had decreased to 2.95 × 10
9/L
for the AMG 108 cohorts, but were only slightly lower
than at baseline in the placebo group (4.03 × 10
9/L). By
week 20 (end of study), the neutrophil counts had essen-
tially returned to baseline: 4.02 × 10
9/L for the AMG 108
cohorts, and 4.10 × 10
9/L for the placebo cohort. In all of
Part B, only two patients had a reversible decrease in
ANC below 1.0 × 10
9/L (but above 0.5 × 10
9/L) at the
lowest measurement, and 11 patients had a reversible
ANC decrease between 1.5 and 1.0 × 10
9/L. Neutrophil
counts of all patients returned to baseline levels as early
as 2 weeks but within 8 weeks after the last injection of
AMG 108 (Figure 2a).
Because suppression of CRP levels is known to be a
pharmacodynamic effect of IL-1 inhibition, a highly sen-
sitive CRP assay was used as part of the chemistry eva-
luations. In Part B patients, a significant (P < 0.001)
difference in median CRP levels favoring AMG 108 over
placebo was observed from week 2 to week 12 and was
maintained at week 16 (P < 0.05), 8 weeks after the last
injection (Figure 2b).
Pharmacokinetics
In Part A (Figure 3a and 3b), mean AMG 108 serum con-
centration-time profiles generally exhibited nonlinear PK,
and serum concentrations increased more than dose pro-
portionately. After a 30-minute IV infusion (100 mg,
300 mg) on day 1, Cmax and AUC0-τ increased approxi-
mately dose proportionately (2.6-fold and 3.2-fold,
respectively; Table 3). However, the Cmax and AUC0-τ
values increased greater than dose proportionately for SC
administration in Part A. After the first SC dose (75 mg,
300 mg) on day 1, Cmax increased 8.2-fold, and AUC0-τ
increased 17.3-fold for a fourfold dose increase (Table 3).
Because of the nonlinear nature of the PK data and insuf-
ficient data for the terminal phase of the concentration-
time profile, the half-life of AMG 108 could not be
determined.
A d d i t i o n a l l y ,a f t e ras i n g l eS Cd o s eo f3 0 0m gA M G
108 in Part A, mean synovial fluid concentrations were
60.3 and 55.4 nM at days 7 and 14, respectively; before
the day-28 dose, the concentration was 39.0 nM. Thus,
monthly SC administration of 300 mg AMG 108
appeared to provide adequate drug exposure above the
estimated IC90 value (approximately 13.5 nM (per ex vivo
data not shown)) in both serum and synovial fluid.
In Part B (Figure 3c), serum concentrations observed
after three SC administrations of 300 mg AMG 108 were
generally within the range observed during Part A; how-
ever, the results should be interpreted with caution, given
the small sample size in Part A (n = 12) compared with
Part B (n = 60 to 65).
An analysis of mean synovial fluid to serum drug con-
centration ratios for nonlavage samples showed a range
from approximately 2% to 45%; however, sample sizes in
this analysis were extremely small (n =1t o3i ne a c h
group]. The ratios for the 75-mg and 300-mg SC groups
were lower on day 2 (2.07% (n = 2) and 9.63% (n =3 ) ,
respectively) than the ratios for the 100-mg and 300-mg
IV groups (23.5% (n = 2) and 26.2% (n = 3), respectively),
suggesting that there might be a time delay between
absorption of AMG 108 after SC injection and subse-
quent distribution to the synovial fluid.
Clinical effects
The mean WOMAC pain scores at baseline were similar
in the AMG 108 group (278.8) and placebo group (268.4)
in Part B. Both groups had decreased WOMAC pain
scores from baseline at week 6, the primary efficacy end
point. Although the difference was not statistically signif-
icant, patients in the AMG 108 group had numerically
greater improvement in pain than did placebo patients
(median LOCF change, -63.0 versus -37.0, respectively;
P = 0.25; Figure 4a). Rescue therapy with NSAIDs or
analgesics was required for six of 72 patients in the AMG
108 group and 10 of 73 patients in the placebo group
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patients or imputing their WOMAC pain scores after
rescue therapy (by using last observation before therapy)
did not affect the overall results.
When patients were stratified for pain at baseline, a
trend in improvement from baseline to week 6 was
observed in the AMG 108 group versus the placebo
group (Figure 4B). When analyzed from lowest to
Panel A:  Median Total Neutrophils Over Time 
 
 
Panel B:  Median C-Reactive Protein Levels Over Time 
mg/L = milligrams per liter 
L = liter 
Figure 2 Laboratory values over time, Part B. (a) Absolute neutrophil count (ANC); (b) C-reactive protein levels over time.
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change from baseline increased from -17.0 to -65.0 to
-109.5 with AMG 108, whereas with placebo, it
remained at approximately -40.0 for each tertile;
however, the differences were not statistically significant
for any tertile (P = 0.45, 0.39, and 0.13, respectively).
The placebo group showed greater, but statistically
insignificant, median change from baseline at week 6
A.  Part A – Intravenous Administration 
 
B.  Part A – Subcutaneous Administration 
C.  Part B – Subcutaneous Administration 
 
 
 
 
Figure 3 Pharmacokinetic results: AMG 108 serum concentrations. (a) part a, intravenous administration; (b) part a, subcutaneous
administration; (c) part b, subcutaneous administration. IV, intravenous; LLOQ, lower limit of quantification; nM, nanomole; SC, subcutaneous.
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Page 8 of 12than did the AMG 108 group in the other two
WOMAC index domains of physical function score
(-170 versus -155, respectively; P = 0.95) and stiffness
(-24 versus -21, respectively; P =0 . 5 9 ) .C o m p o s i t e
WOMAC scores at week 6 showed approximately equal
changes in both groups (-270 versus -263, placebo ver-
sus AMG 108, respectively; P = 0.97). By week 12 of the
study, patients in the AMG 108 group had greater med-
ian improvements in the WOMAC composite score
(pain, physical function, and stiffness), compared with
the placebo group (median observed change in compo-
site score -436 versus -314, respectively), although the
difference was not statistically significantly different (P =
0.48). Changes in additional end points (for example,
physician and patient global assessments of pain, the
SF-36, and the EQ-5D) were insignificant and are not
reported herein.
The study was suspended by the sponsor to investigate
the fatal serious adverse event in a patient in the AMG
108 300-mg IV group in Part A, after which the study
was resumed and completed. The AMG 108 program in
OA was terminated because of lack of demonstrable
clinical benefit.
Discussion
In this two-part, randomized, double-blind multiple-dose
study in patients with OA of the knee, AMG 108 was
well tolerated when administered SC (75 and 300 mg) or
IV (100 and 300 mg). Most AEs, infectious AEs, serious
AEs and infections, and withdrawals from study due to
AEs occurred at similar rates in the AMG 108 and pla-
cebo groups. One death was reported in an 80-year-old
patient (Part A, 300-mg IV AMG 108; complications of
lobar pneumonia). AMG 108 serum concentration-time
profiles generally exhibited nonlinear PK during the
study, and levels of study drug in both serum and syno-
vial fluid appeared to be adequate for IL-1 inhibition. A
nonstatistically significant trend toward clinical effect
was observed, particularly in the subset with high VAS
pain scores at baseline; the AMG 108 group in Part B
had numerically greater but statistically insignificant
improvement in pain than did the placebo group, as
shown by the WOMAC scores (median change, -63.0
versus -37.0, respectively). However, the clinical rele-
vance of the changes is not clear. The expected effects of
IL-1 inhibition were demonstrated in decreased CRP and
mean neutrophil counts.
It has been shown that IL-1 plays an important role in
preclinical models of OA [13] and in studies of human
cartilage and bone [18]. IL-1 may also have an effect on
the pain of OA, although this was not observed in a
study by Richette et al. [7] However, despite a signifi-
cant difference between the AMG 108 and placebo
groups in CRP values, a biologic effect of IL-1 inhibi-
tion, the primary end point (significant improvement in
WOMAC-measured pain) was not reached in this study,
nor was it reached in a study of autologous IL-1ra
(orthokin) by Yang et al. (16.8% versus 16.5%, orthokin
versus placebo, respectively) [19].
Decreases in neutrophil counts have been observed in
RA patients receiving anti-IL-1 therapies; results of clini-
cal studies in OA patients have also shown these changes
[13,16,20]. In the current study, AMG 108 administration
was associated with decreases in ANCs and platelets,
which returned to baseline values at the end of study.
Infections appeared to occur at greater frequencies in the
high-dose SC groups compared with placebo; however,
the incidence of serious infections was similar in the
AMG 108 and placebo groups.
Pharmacokinetic evaluation of both synovial fluid and
serum in this study suggested that adequate IL-1 inhibi-
tion should have been achieved with the dose and fre-
quency of AMG 108 administered (trough concentrations
exceeded the IC90 value for IL-1b-induced IL-6 inhibition
Table 3 Pharmacokinetic data after intravenous and subcutaneous administration of AMG 108
AMG 108 dose and route of administration
100 mg IV 300 mg IV 300 mg SC 75 mg SC
Day 1 (first dose) (n = 12) (n = 12) (n = 12) (n = 12)
Cmax (nM; mean (SD)) 312 (72) 806 (112) 220 (58) 26.7 (12.9)
Tmax (hr; median (range)) 1.0 (0.5-24.0) 1.0 (0.5-12.0) 144 (144-335) 144 (48-145)
AUC0-τ (nM; mean (SD)) 2,580 (665) 8,280 (1,690) 4,230 (1,210) 244 (156)
Trough concentration (nM; mean (SD)) 14.9 (15.2) 148 (48) 96.3 (38.3) BQL
Day 56 (third dose) (n = 12) (n =8 )
a (n = 12) (n =6 )
a
Cmax (nM; mean (SD)) 315 (91) 960 (192) 397 (123) 41.4 (11.1)
Tmax (hr; median (range)) 0.51 (0.50-8.0) 0.51 (0.50-8.1) 168 (48-336) 48 (48-169)
AUC0-τ (nM; mean (SD)) 2,700 (1,360) 12,000 (2,230) 8,610 (3,010) 449 (213)
Trough concentration (nM, mean (SD)) 22.5 (32.3) 257 (93) 216 (100) BQL
AUC0-τ,area under the concentration-time curve, estimated by using a linear/log trapezoidal method from days 1 to 28 for the first dose and days 56 to 84 for
the third dose; BQL, below the quantification limit; Cmax, maximum observed serum concentration; hr, hour; IV, intravenous; nM, nanomolar; SC, subcutaneous;
SD. standard deviation; Tmax, time to Cmax.
aPatients who did not receive all 3 doses of study medication were excluded from group mean for day 56.
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Page 9 of 12Panel A:  LOCF and Observed Changes from Baseline 
 
Panel B:  Change from Baseline, By Stratification for Pain at Baseline 
 
Figure 4 Median change from baseline in WOMAC pain scores. (a) Last observation carried forward (LOCF) and observed change from
baseline. Note: Primary LOCF analysis at week 6 includes only the evaluable patients randomized to the WOMAC study (one AMG 108 patient
was not evaluable); observed analyses at weeks 6 and 12 include all evaluable patients. (b) Change from baseline, by stratification for pain at
baseline. dGEMRIC, delayed gadolinium-enhanced magnetic resonance imaging of cartilage; LOCF, last observation carried forward; WOMAC,
Western Ontario and McMaster Universities osteoarthritis index pain score.
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Page 10 of 12at trough levels in both serum and synovial fluid). How-
ever, it was not possible to evaluate the penetration of
AMG 108 into the deeper cartilage layers in this study,
and the availability of the drug to chondrocytes in cartilage
lacunae remains a possible limitation of this strategy for
IL-1 inhibition. Another possible limitation was that
patients were required to hav eo n l yo n ek n e ee v a l u a t e d ,
and it was not required to be erosive; eligibility criteria
that required more inflammatory or widespread OA might
have resulted in a more robust clinical effect. Although a
nonsignificant trend toward clinical benefit was suggested
in this study in subjects with a high baseline VAS, the
magnitude of the benefit was not considered large enough
to pursue development of AMG 108 for the OA
indication.
Conclusions
Overall, the safety profile of AMG 108 was similar to
placebo in this short, 3-month study, but minimal if any
clinical benefit was observed in patients with OA of the
knee. Potential areas for further research of IL-1 inhibi-
tion in OA may include varieties of OA that respond
poorly to available therapies (for example, inflammatory
OA or erosive OA of the hands).
Additional material
Additional file 1: dGEMRIC imaging, analysis and results.
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